Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
The smoking cessation medications varenicline and bupropion do not increase the risk of moderate-to-severe neuropsychiatric adverse events, including among smokers with stable psychiatric disorders, according to the largest trial of pharmacotherapy for smoking cessation to date (Anthenelli RM et al. Lancet. doi:10.1016/S0140-6736(16)30272-0 [published online April 22, 2016]). The trial, funded by Pfizer and GlaxoSmithKline, was requested by the US Food and Drug Administration following concerns about the neuropsychiatric safety of the. The study is also the first comparative efficacy trial of the 3 first-line smoking cessation drugs .
Slomski A. Smoking Cessation Drugs Pose Little Neuropsychiatric Risk. JAMA. 2016;315(24):2656. doi:10.1001/jama.2016.7814